FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation
Introduction
Rheumatoid arthritis (RA) is a chronic progressive disease that affects quality of life (QOL) [1]. It is an autoimmune disorder of unknown etiology characterized by joint inflammation, leading to disability [2]. Disability, which is quantified by the Health Assessment Questionnaire (HAQ) and is largely associated with the decrease in activity, has a significant impact on QOL in RA patients [3], [4]. Decrease in activity is closely correlated with pain in RA patients, and is often caused and exacerbated by several inflammatory mediators (prostaglandin E2 and inflammatory cytokines) [5], [6], [7]. Decrease in activity is also correlated with a decrease in muscle strength and joint destruction in RA patients [8]. The decrease in muscle strength is improved with anti-inflammatory therapy [9]. Joint destruction is mediated by enzymes such as serine proteases, matrix metalloproteinases and cathepsins, which can be induced by inflammatory cytokines [10]. Pain, the decrease in muscle strength and joint destruction can be induced by inflammation, and subsequently cause a decrease in activity in RA patients. Decreased activity in RA patients includes a problem that puts them at increased risk of additional conditions, such as heart disease, diabetes and high blood pressure [4]. Within 10 years of diagnosis, 50% of patients are too disabled to work and up to 60% of patients with RA face significant disruption to routine activities of daily living [11], [12], [13], [14], [15]. Therefore, it is an important goal to ameliorate the decrease in activity for treatment of RA.
FK506 (tacrolimus) is a new drug used therapeutically for RA patients. FK506 is a calcineurin inhibitor, suppressing activation of T cells by inhibiting nuclear localization of NFAT [16]. FK506 suppresses T cell-derived cytokines [17] and antigen presenting cell-derived inflammatory cytokines, TNFα and IL-1β, in the presence of T cell activation [18], [19]. Clinically, FK506 improves QOL for RA patients who do not tolerate with methotrexate (MTX) well [20], [21]. Phase II studies showed that FK506 significantly improves physical function, pain and joint inflammation in RA patients [20], [21]. Recent studies demonstrate that FK506 suppresses inflammation-related pain in an adjuvant-induced arthritis model when paw edema is suppressed by FK506 [22]. However, the mechanism by which FK506 ameliorates the decrease in activity in RA patients and the relationship between activity and inflammation have not been characterized.
In this study, we investigated the relationship between the effect of FK506 on spontaneous locomotor activity and inflammation, and also compared spontaneous locomotor activity to pain, muscle strength and joint destruction in a collagen-induced arthritis (CIA) rat model.
Section snippets
Drugs
A solid dispersion formulation of FK506 [23] was prepared at Fujisawa Pharmaceutical (Osaka, Japan). MTX was purchased from Sigma (St. Louis, MO, USA). FK506 was suspended in distilled water and MTX was suspended in 0.5% methylcellulose.
Animals
Lewis female rats (130–150 g) in specific pathogen free conditions were purchased from Charles River Japan (Yokohama, Japan) at the age of 6 or 7 weeks. Animals were maintained in groups of 5 for at least 7 days on a 12 h light–dark cycle (lights on from 0700 to
Therapeutic treatment with FK506 recovers body weight in CIA rats
Lewis rats were immunized with type II collagen from day 0, and paw inflammation of CIA rat was characterized with paw swelling and histopathological analysis of ankle joint. Paws of CIA rat swelled, and inflammatory cells infiltrated into ankle joint from day 11 (Fig. 1C, data not shown). On day 35, both infiltration of inflammatory cells into ankle joint and pannus formation were observed in CIA rats (Fig. 2B). The effect of FK506 and MTX in CIA rat was then examined.
When FK506 (3.2 mg/kg) or
Discussion
This study demonstrates that FK506 ameliorates spontaneous locomotor activity in CIA rats via an alternative pathway for suppression of inflammation. Therapeutic treatment with FK506 significantly ameliorated spontaneous locomotor activity in CIA rats from day 27 (Fig. 3). However, FK506 did not improve either paw swelling or infiltration of inflammatory cells into ankle joint until day 35 (Fig. 1, Fig. 2). These results indicate that FK506 ameliorates spontaneous locomotor activity, and that
References (28)
The epidemiology of rheumatoid arthritis
Rheum. Dis. Clin. North Am.
(2001)- et al.
Pain-related disability and effects of chronic morphine in the adjuvant-induced arthritis model of chronic pain
Physiol. Behav.
(1997) - et al.
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids)
Int. Immunopharmacol.
(2001) Rheumatoid arthritis: pathophysiology and implications for therapy
N. Engl. J. Med.
(1990)- et al.
Measurement of patient outcome in arthritis
Arthritis Rheum.
(1980) - et al.
Advances in rheumatology: coxibs and beyond
J. Pain Symp. Manag.
(2003) - et al.
Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis
Ann. Rheum. Dis.
(2004) - et al.
Mechanisms of pain in arthritis
Ann. N.Y. Acad. Sci.
(2002) Effectiveness and safety of strength training in rheumatoid arthritis
Curr. Opin. Rheumatol.
(2004)- et al.
A comparison of the effects of tenoxicam and piroxicam on grip strength in patients with rheumatoid arthritis
Scand. J. Rheumatol., Suppl.
(1989)
Mechanism of joint destruction in rheumatoid arthritis
Arch. Immunol. Ther. Exp. (Warsz)
Rheumatoid arthritis: current clinical and research directions
J. Women's Health
Long-term outcomes in rheumatoid arthritis
Br. J. Rheumatol.
The socioeconomic impact of chronic pain
Disabil. Rehabil.
Cited by (20)
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo
2017, Life SciencesCitation Excerpt :In autoimmune diseases, several pharmacological mechanisms for the actions of MTX have been proposed; inhibition of T-cell proliferation is largely responsible for its immunosuppressive and anti-inflammatory effects [26,27]. Additionally, tacrolimus, a calcineurin inhibitor, reportedly inhibited T-cell proliferation but had no suppressive effects in rat CIA model when administered after the onset of arthritis [28]. These findings reveal that anti-inflammatory drugs that inhibit T-cell functions are not able to improve CIA in a therapeutic regimen, possibly because the period for dosing is after T-cell activating phase in the pathogenesis of CIA.
Possible involvement of glutamatergic signaling machineries in pathophysiology of rheumatoid arthritis
2011, Journal of Pharmacological SciencesExcitatory amino acid transporters expressed by synovial fibroblasts in rats with collagen-induced arthritis
2005, Biochemical PharmacologyCitation Excerpt :Although the pathogenesis and etiology of this disabling disease are not well understood to date, activated synovial fibroblasts are thought to be a key player in mechanisms underlying the joint destruction in RA [1,2]. Type-II collagen-induced arthritis (CIA) in Lewis rats is a widely used experimental animal model of inflammatory polyarthritis with clinical and pathological features similar to those seen with RA in humans, which are dependent on both humoral and cellular immunity to the immunizing antigen [3,4]. Previous studies have demonstrated a drastic increase in endogenous levels of both glutamate (Glu) and aspartate in the synovial fluid obtained from patients with arthritis [5].
FK506 inhibits prostaglandin E<inf>2</inf> production from synovial cells by suppressing peripheral blood mononuclear cells
2005, International ImmunopharmacologyThe role of proteasome in muscle wasting of experimental arthritis
2023, Advances in RheumatologyAnti-rheumatic and Memory-enhancing Effect of Memantine on Complete Freund’s Adjuvant-induced Rheumatoid Arthritis Compared to Methotrexate in Wistar Rats
2023, Journal of Pharmacology and Pharmacotherapeutics